##gff-version 3
##sequence-region P10916 1 166
P10916	UniProtKB	Initiator methionine	1	1	.	.	.	Note=Removed;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:P51667	
P10916	UniProtKB	Chain	2	166	.	.	.	ID=PRO_0000198727;Note=Myosin regulatory light chain 2%2C ventricular/cardiac muscle isoform	
P10916	UniProtKB	Domain	24	59	.	.	.	Note=EF-hand 1;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00448	
P10916	UniProtKB	Domain	94	129	.	.	.	Note=EF-hand 2;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00448	
P10916	UniProtKB	Domain	130	165	.	.	.	Note=EF-hand 3;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00448	
P10916	UniProtKB	Calcium binding	37	48	.	.	.	.	
P10916	UniProtKB	Modified residue	2	2	.	.	.	Note=N%2CN%2CN-trimethylalanine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:P51667	
P10916	UniProtKB	Modified residue	14	14	.	.	.	Note=Deamidated asparagine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20445002;Dbxref=PMID:20445002	
P10916	UniProtKB	Modified residue	15	15	.	.	.	Note=Phosphoserine%3B by ZIPK/DAPK3;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:20038585,ECO:0000269|PubMed:20445002;Dbxref=PMID:20038585,PMID:20445002	
P10916	UniProtKB	Modified residue	19	19	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:P51667	
P10916	UniProtKB	Modified residue	52	52	.	.	.	Note=Phosphothreonine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:P08733	
P10916	UniProtKB	Natural variant	13	13	.	.	.	ID=VAR_004601;Note=In CMH10%3B with mid-left ventricular chamber thickening%3B decrease calcium binding affinity%3B large increase in its calcium binding affinity upon phosphorylation. A->T;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11102452,ECO:0000269|PubMed:8673105;Dbxref=dbSNP:rs104894363,PMID:11102452,PMID:8673105	
P10916	UniProtKB	Natural variant	18	18	.	.	.	ID=VAR_004602;Note=In CMH10%3B decrease calcium binding affinity. F->L;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11102452,ECO:0000269|PubMed:9535554;Dbxref=dbSNP:rs104894370,PMID:11102452,PMID:9535554	
P10916	UniProtKB	Natural variant	22	22	.	.	.	ID=VAR_004603;Note=In CMH10%3B some patients present with mid-left ventricular chamber thickening%3B significantly decrease calcium binding affinity%3B loss of phosphorylation. E->K;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11102452,ECO:0000269|PubMed:12404107,ECO:0000269|PubMed:8673105;Dbxref=dbSNP:rs104894368,PMID:11102452,PMID:12404107,PMID:8673105	
P10916	UniProtKB	Natural variant	57	57	.	.	.	ID=VAR_029449;Note=G->R;Dbxref=dbSNP:rs2428140	
P10916	UniProtKB	Natural variant	58	58	.	.	.	ID=VAR_004604;Note=In CMH10%3B impairs calcium binding%3B bind calcium upon phosphorylation. R->Q;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11102452,ECO:0000269|PubMed:12404107,ECO:0000269|PubMed:12818575,ECO:0000269|PubMed:9535554;Dbxref=dbSNP:rs104894369,PMID:11102452,PMID:12404107,PMID:12818575,PMID:9535554	
P10916	UniProtKB	Natural variant	95	95	.	.	.	ID=VAR_004605;Note=In CMH10%3B with mid-left ventricular chamber thickening%3B decrease calcium binding affinity. P->A;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11102452,ECO:0000269|PubMed:8673105;Dbxref=dbSNP:rs121913658,PMID:11102452,PMID:8673105	
P10916	UniProtKB	Natural variant	166	166	.	.	.	ID=VAR_019844;Note=In CMH10. D->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12707239;Dbxref=dbSNP:rs199474815,PMID:12707239	
